Krystal Biotech holder plans $9.3M stock sale

A Rule 144 notice reports a planned sale of 25,000 Krystal Biotech (KRYS) founder shares with an aggregate market value of about $9.29 million.

Rhea-AI Filing Summary

Krystal Biotech, Inc. (KRYS) is the issuer of common stock that Suma Krishnan has notified under Rule 144 of an intention to sell. The notice covers up to 25,000 shares of common stock, to be sold through Morgan Stanley Smith Barney LLC on NASDAQ.

The shares are described as Founders Shares, acquired from Krystal Biotech on March 31, 2017. The filing lists an aggregate market value for the planned sale of approximately $9,286,750. The form indicates no other Rule 144 sales by the filer in the past three months.

Key Figures

Shares covered by Rule 144 notice: 25,000 shares of common stock Aggregate market value of shares: $9,286,750 Acquisition date of shares: March 31, 2017 +1 more

4 metrics

Shares covered by Rule 144 notice 25,000 shares of common stock Maximum number of Krystal Biotech shares to be sold under the Rule 144 filing

Aggregate market value of shares $9,286,750 Aggregate market value for the 25,000 shares covered by the Rule 144 notice

Acquisition date of shares March 31, 2017 Date the founders shares were acquired from Krystal Biotech, Inc.

Planned sale mechanism Rule 144 sale on NASDAQ Securities to be sold through Morgan Stanley Smith Barney LLC under Rule 144

Key Terms

Rule 144, Founders Shares, aggregate market value

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Founders Shares financial

"Common | 03/31/2017 | Founders Shares | Issuer"

Founders shares are a special block of a company’s stock originally given to the people who started the business; they often carry extra voting power or favorable terms compared with regular shares. For investors, these shares matter because they concentrate control and influence how future funding, ownership dilution, and decision-making will play out—think of founders shares as the steering wheel that can steer a company’s direction even as more passengers (investors) climb aboard.

aggregate market value financial

"Common | Morgan Stanley Smith Barney LLC ... | 25000 | 9286750.00"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

What Rule 144 transaction was reported for Krystal Biotech (KRYS)?

The notice reports an intention by Suma Krishnan to sell up to 25,000 shares of Krystal Biotech common stock under Rule 144, with sales to be executed through Morgan Stanley Smith Barney LLC on NASDAQ.

What is the aggregate market value of the KRYS shares in this Rule 144 filing?

The filing reports an aggregate market value of approximately $9,286,750 for the 25,000 shares of Krystal Biotech common stock covered by this Rule 144 notice.

When were the KRYS shares in this Rule 144 notice originally acquired?

The shares were acquired on March 31, 2017. They are identified as Founders Shares acquired from Krystal Biotech, Inc..

Has the filer sold any KRYS shares under Rule 144 in the past three months?

The section for Securities Sold During The Past 3 Months does not list any transactions, indicating no reported Rule 144 sales of Krystal Biotech shares by the filer in that period.

Which broker is listed for the planned KRYS Rule 144 sale?

The Rule 144 notice lists Morgan Stanley Smith Barney LLC Executive Financial Services, at New York Plaza, as the broker for the planned sale of 25,000 shares of Krystal Biotech common stock on NASDAQ.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 04:35 PM Accepted by SEC EDGAR 09/04/2026 - 04:34 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001298711
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Krystal Biotech, Inc.
SEC File Number	001-38210
Address of Issuer	2100 Wharton Street, Suite 701 Pittsburgh PENNSYLVANIA 15203
Phone	4125865830
Name of Person for Whose Account the Securities are To Be Sold	SUMA KRISHNAN
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director
Relationship to Issuer	Officer
Relationship to Issuer	10% Stockholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	25000	9286750.00	29598836	09/04/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/31/2017	Founders Shares	Issuer			25000	03/31/2017	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/04/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/04/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Suma Krishnan
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)